Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
1998-03-10
2001-01-30
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C530S399000
Reexamination Certificate
active
06180107
ABSTRACT:
BACKGROUND OF THE INVENTION
A new class of cell-derived dimeric mitogens with apparently restricted specificity for vascular endothelial cells has recently been identified and generally designated vascular endothelial cell growth factor (VEGF). The mitogen has been purified from: conditioned growth media of rat glioma cells, [Conn et al.,
Proc. Natl. Acad. Sci. USA
87: 2628-2632 (1990)]; conditioned growth media of bovine pituitary folliculo stellate cells [Ferrara and Henzel,
Biochem. Biophys. Res. Comm.
161: 851-858 (1989) and Gospodarowicz et al.,
Proc. Natl. Acad. Sci. USA
86: 7311-7315 (1989)]. Vascular endothelial growth factor I (VEGF I) is a homodimer with an apparent molecular mass of 46 kDa, with each subunit having an apparent molecular mass of 23 kDa. VEGF I has distinct structural similarities to platelet-derived growth factor (PDGF), a mitogen for connective tissue cells but not vascular endothelial cells from large vessels.
SUMMARY OF THE INVENTION
Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer and stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair. The present invention provides a novel vascular endothelial growth factor II (VEGF II) free of other proteins and provides a procedure for its purification. VEGF II is also provided which stimulates endothelial cells for induction of blood vessel growth, vascular repair, the production of artificial blood vessels and tissue repair.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5338840 (1994-08-01), Bayne et al.
patent: 0186084 (1985-12-01), None
patent: 0259 953 (1988-03-01), None
patent: 0399 816 (1990-11-01), None
patent: WP89/088700 (1992-01-01), None
patent: WP 90/181364 (1992-01-01), None
Ferrara & Henzel, ‘Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells’, Biochem. Biophys. Res. Comm. 161: 851-858, 1989.
Laemmli, ‘Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4’, Nature, 227: 680-684 (1970).
Saiki et al. ‘EnzymaticAmplification of Beta-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia’ Science, 230: p. 1350-1354, (1985).
Frohman et al. ‘Rapid production of full-length cDNAs from rare transcripts: . . . gene-specific oligonucleotide primer’ Proc. Natl. Acad. Sci, USA 85, 8998-9002 (1988).
Tischer et al. ‘Vascular Endothelial Growth Factor: A new member of the platelet derived growth factor gene Family’, Biochem. & Biophysical Res. Comm. 165: 1198, (1989).
Conn et al. Proc. Natl. Acad. Sci. USA 87: p. 1323-1327 (1990).
Keck et al. ‘Vascular Permeability Factor an Endothelial Cell Mitogen Related to PDGF’, Science, 246: p. 1309-1312 (1989).
Bowie et al.‘Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions’, Science 247: p. 1306-1310 (1989).
Conn, Endothelial Cell Growth Factors, Yeshiva University, 1987.
Gospodarowicz et al. ‘Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells’, Proc. Natl. Acad. Sci. USA 86: p. 7311-7315 (1989).
Joukov et al. ‘A Novel vascular endothelial growth factor. VEGF-C, . . . receptor tyrosine kinases’, Embo. J., vol. 15 pp. 290-298 (1996).
Leung et al. (1989) Science 246, p. 1306-1309.
Conn et al. (1990) PNAS USA 87, p. 2628-2632.
Bayne Marvin L.
Conn Gregory L.
Thomas, Jr. Kenneth A.
Hand J. Mark
Merck & Co. , Inc.
Spector Lorraine
Tribble Jack L.
LandOfFree
Vascular endothelial cell growth factor II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vascular endothelial cell growth factor II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular endothelial cell growth factor II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2539152